Sitemap
The following sitemap is for search indexing purposes only. More convenient structure is provided through site navigation or search feature.-
BTMF Contribution Form 2019
-
Fast Facts - GHVD of the Stomach and Intestines
-
Search-BTM
-
Contact Us
- Post-Transplant Care
- Transplant Therapy and Donor Matching
-
Medical Education & Research
-
Education Catalog
- After the Results Quality of Life Pre- and Post-Transplant
- Predicting and Addressing Relapse After HCT
- Setting Up Patients for HCT and Cellular Therapy Success
- The Evolution of HCT Self-Paced Learning Course
- State of the Science in Ensuring a Donor for All
- Structural Racism and AML
- Increasing Access to HCT for Sickle Cell Disease
- Evidence for Shared Care in HCT
- Advances in HCT Over Time
- NMDP/Be The Match Research and Resource Videos
- Overcoming Barriers to HCT and Improving Access
- After the Results: Improving HCT Equity and Access
- Explore Cell Therapy Podcast
- Quality of Life Pre and Post Transplant
- After the Results: Functional vs. Chronological Age
- Timing for HCT Consultation Guidelines
- After the Results: Evolving GVHD Prophylaxis Strategies for HLA-mismatched HCT
- Webinar: Enhance Your Service Offerings with Related Donor Services
- AML Risk Stratification: Influence of Emerging Cytogenetics and Molecular Markers on Treatment Decisions
- Making AML Therapy Decisions at First Remission
-
Materials Catalog
- Get a Restful Sleep - Tips for patients and caregivers
- Caregivers Companion book
- Caregiver Support Services Info Card
- Blood and Marrow Transplant Journeys - Ordinary people with extraordinary stories
- Fertility and Family Planning Info Card
- CAR T Cell Therapy Basics
- Blood and Marrow Transplant (BMT) An Introduction to Allogeneic BMT
- PTLD Clinical Trial (SOT)
- PTLD Clinical Trial (HCT)
- Living With Chronic GVHD
- Communicating with your Transplant Recipient
- Communicating with your BMT Donor
- Fast Facts - Extracorporeal Photopheresis
- Fast Facts - GVHD of the Vulva and Vagina
- AML Treatment Conversation Guide
- Basics of Blood and Marrow Transplant Videos
- Your Guide to BMT Resources and Support - Spanish
- Government Finance and Insurance Programs
- Your Guide to BMT Resources and Support
- Fast Facts - GVHD of the Lungs
- Fast Facts - Chronic GVHD of the Skin
- Allogeneic Transplant - How to Plan and What to Expect
- Preparing for Transplant
- The Allogeneic Transplant Process
- The Basics of Blood and Marrow Transplant
- Fast Facts - Chronic GVHD of the Mouth
- Haploidentical Transplant Fact Sheet
- Basics of Graft-versus-host Disease
- Word List
- Fertility and Transplant – For Men Fact Sheet
- Fertility and Transplant – For Women Fact Sheet
- Raising Money to Pay for Transplant Fact Sheet
- Financial Planning Before Transplant
- Transplant and Affordable Care Act
- Transplant and Hodgkin Lymphoma Patient Fact Sheet
- Patient Support Center Promo Card
- Transplant and Multiple Myeloma Patient Fact Sheet
- Peer Connect Program Information Card
- The Donor Search Process
- Transplant as an Option for Adults Over 50 - Spanish
- Transplant Basics - Spanish
- Living Now Magazine, Parent Caregiver Issue
- Considering Clinical Trials Patient Fact Sheet
- Transplant and Wiskott-Aldrich Syndrome Patient Fact Sheet
- Transplant and MLD Patient Fact Sheet
- Transplant and ALD Patient Fact Sheet
- Transplant and Hurler Syndrome Patient Fact Sheet
- Transplant and SCID Patient Fact Sheet
- Transplant and Severe Aplastic Anemia Patient Fact Sheet
- Transplant and Krabbe Disease Patient Fact Sheet
- Transplant and MDS Patient Fact Sheet
- Transplant and AML Patient Fact Sheet
- Transplant and CLL Patient Fact Sheet
- Transplant and CML Patient Fact Sheet
- Transplant and NHL Patient Fact Sheet
- Patient After Transplant App Information Card
- Super Sam vs Marrow Monsters Worksheets
- Post-Transplant Guidelines for Patients - Spanish
- Living Now Magazine, Caregiver Issue - Spanish
- Living Now Magazine, Issue 6 - Spanish
- Living Now Magazine, Issue 5 - Spanish
- Living Now Magazine, Issue 4 - Spanish
- Living Now Magazine, Issue 3 - Spanish
- Living Now Magazine, Issue 2 - Spanish
- Living Now Magazine, Issue 1 - Spanish
- Living Now Magazine, Caregiver Issue
- Living Now Magazine, Issue 6 - 2+ Years
- Living Now Magazine, Issue 5, 18-24 months
- Living Now Magazine, Issue 4, 12-18 months
- Living Now Magazine, Issue 3, 9-12 months
- Living Now Magazine, Issue 2, 6-9 Months
- Living Now Magazine, Issue 1 - Returning Home
- Insights Video for Young Adults
- Super Sam vs Marrow Monsters Video
- Transplant Outcomes and Treatment Decisions
- Transplant as an Option for Adults Over 50
- Transplant Basics - Understanding Transplant and How It Works
- Advances in Transplant E-News
- AML Clinical Decision Aid
- HCT Guidelines for Consultation Timing
-
HCT Presentation Slides
- Myeloproliferative Neoplasms (MPN), Transplant Consultation Timing Guidelines
- Hemaglobinopathies, Transplant Consultation Timing Guidelines
- Trends in Selected Diseases, Autologous HCT
- Haploidentical HCT Recipients in the U.S., by Graft Type
- Allogeneic HCT Recipients in the U.S. by Donor Type
- Trends in Allogeneic HCT in the U.S. for Selected Diseases
- Common Conditioning Regimens in AML or MDS Allogeneic HCT between 2007-2017
- Myelodysplastic Syndromes - Pediatric, Transplant Consultation Timing Guidelines
- Myeloproliferative Neoplasms, Transplant Consultation Timing Guidelines
- NHL Survival, Unrelated PBSC HCT, with a Prior Autologous HCT, by Disease Status
- NHL Survival, Unrelated Marrow HCT, with a Prior Autologous HCT, by Disease Histology
- NHL Survival, Unrelated Non-Myeloablative HCT, in Adults with Prior Autologous HCT, By Cell Source
- Unrelated Donor HCT in Patients 18 Years and Older, by Graft Source
- Allogeneic HLA-Matched Sibling Donor HCT, in Patients 18 Years and Older, by Graft Source
- Allogeneic HLA-Matched Sibling Donor HCT, in Patients Less Than 18 Years, by Graft Source
- Myeloproliferative Diseases, Survival after Unrelated Donor HCT, by Disease
- Myeloproliferative Diseases, Survival after HLA-Matched Sibling HCT, by Disease
- Multiple Myeloma Autologous HCT Survival by Year of Transplant
- Unrelated Donor Allogeneic Transplants in Pediatric Patients
- AML - 2019 Slides for Presentations
- Hodgkin Lymphoma Survival - Allogeneic HCT, by Donor Type
- Non-Malignant Diseases, Transplant Consultation Timing Guidelines
- Other Malignant Diseases, Transplant Consultation Timing Guidelines
- Multiple Myeloma, Transplant Consultation Timing Guidelines
- Myelodysplastic Syndromes, Transplant Consultation Timing Guidelines
- CLL, Transplant Consultation Timing Guidelines
- AML - Pediatric, Transplant Consultation Timing Guidelines
- ALL - Pediatric, Transplant Consultation Timing Guidelines
- MDS Survival, Unrelated Donor HCT, by Disease Status
- HCT Activity Over Time, U.S. by Donor Type
- Unrelated Donor HCT Survival Over Time, by Disease
- Transplant Referral Timing Guidelines - 2019
- Trends in Allogeneic Transplants by Recipient Age
- Trends in Autologous Transplants by Recipient Age
- Severe Aplastic Anemia Survival, Allogeneic HCT in Pediatric Patients, by Donor Type
- Severe Aplastic Anemia Survival, Allogeneic HCT in Adults, by Donor Type
- Follicular Lymphoma Survival, Allogeneic HCT, by Disease Status and Donor Type
- ALL Survival, Unrelated HCT, Age ≥ 18 years, by Disease Status
- National Marrow Donor Program Be The Match FY17 Annual Numbers
- Likelihood of Finding a Matching Available Adult Donor or CBU with Adequate Cell Dose, Adult Patients, by Ethnic Background
- Likelihood of Finding a Matching Available Adult Donor or CBU with Adequate Cell Dose, Pediatric Patients, by Ethnic Background
- Likelihood of Finding a Matching CBU with Adequate Cell Dose, Pediatric Patients, by Ethnic Background
- Likelihood of Finding a Matching CBU with Adequate Cell Dose, Patients ≥20 Years, by Ethnic Background
- Likelihood of Finding a Matched and Available Adult Donor on the Be The Match Registry, by Ethnic Background
- CLL Survival Over Time, Unrelated HCT
- MDS Survival, HLA-Matched Sibling Donor HCT, by Disease Status
- AML Pediatric Survival, HLA-Identical Sibling HCT, by Disease Status
- MDS Adult Unrelated HCT Improved Survival Over Time
- NHL Survival Over Time, Unrelated HCT, with Prior Autologous HCT
- Follicular Lymphoma Survival after Autologous HCT, by Treatment Response
- CML Survival, HLA-Identical Sibling HCT, by Disease Status
- Causes of Death after Sibling Donor Transplants
- Causes of Death after Unrelated Donor Transplants
- Causes of Death after Autologous Transplants
- Diversity of Cord Blood Units Listed on the Be The Match Registry
- Growth in the Number of Cord Blood Units on the Be The Match Registry
- Growth of Adult Unrelated Donors on the Be The Match Registry
- Number of Unrelated Donor Transplants, by Cell Source
- Role of Cord Blood in Unrelated Donor HCT for Patients of Hispanic or Latino Ethnic Background
- Role of Cord Blood in Unrelated Donor HCT by Patient Ethnic Background
- Unrelated Donor HCT by Patient Diagnosis, Non-Malignant Diseases
- Unrelated Donor HCT by Patient Diagnosis, Malignant Diseases
- Unrelated Donor HCT by Patient Diagnosis, Malignant Diseases, by Year
- Unrelated Donor HCT by Patient Ethnic Background
- Unrelated Donor HCT by Recipient Age and Year
- Unrelated Donor HCT, Distribution of Cell Sources
- Unrelated Donor HCT for White Patients
- Unrelated Donor HCT for Patients of Hispanic or Latino Ethnic Background
- Unrelated Donor HCT for Native Hawaiian and Other Pacific Islander
- Unrelated Donor HCT for People of Color by Cell Source
- Unrelated Donor HCT for People of Color and White Patients
- Unrelated Donor HCT for American Indian and Alaska Native Patients
- Unrelated Donor HCT for African American Patients
- Unrelated Donor HCT for Asian Patients
- Number of Unrelated Donor Transplants, Adult Recipients, by Cell Source
- Growth in the Number of Unrelated Donor Transplants
- Number of Unrelated Donor Transplants, Pediatric Recipients, by Cell Source
- Growth of Adult Donors and Cord Blood Units on the Be The Match Registry
- Diversity of Adult Donors on the Be The Match Registry
- One-Year Survival, NMDP-Be The Match Transplants
- NHL Survival Over Time, Unrelated HCT
- AML Survival in Adults, Over Time, Unrelated HCT
- AML in Adults, Unrelated HCT Over Time, By Age
- NHL Unrelated Donor HCT, By Age, Over Time
- Sickle Cell Disease Survival, Pediatric, Unrelated HCT
- Thalassemia Survival, Unrelated HCT
- Hodgkin Lymphoma Survival, Unrelated HCT
- Hurler, ALD, MLD Survival, Pediatric, Unrelated HCT
- ALD, MLD Survival, Pediatric, Unrelated Marrow HCT
- Hurler Syndrome Survival, Pediatric, Unrelated Marrow HCT
- Wiscott-Aldrich Syndrome Survival, Pediatric, Unrelated Marrow HCT
- SCID Survival, Pediatric, Unrelated Cord Blood HCT
- SCID Survival, Pediatric, Unrelated Marrow HCT
- Fanconi Anemia Survival, Pediatric, Unrelated HCT, by Cell Source
- Severe Aplastic Anemia Survival, Unrelated Marrow HCT, by Age
- NHL Survival, Unrelated HCT, Non-Myeloablative, By Cell Source
- NHL Survival, Unrelated Marrow HCT, By Disease Histology
- NHL Survival, Unrelated PBSC HCT, By Disease Histology
- MDS Survival, Unrelated HCT, Age ≥55 Years, by Preparative Regimen
- MDS Survival, Unrelated HCT, by Age
- MDS Survival, Unrelated PBSC HCT, by Disease Classification
- MDS Survival, Unrelated Marrow HCT, by Disease Classification
- Immune Syndromes SCID and WAS Survival, Unrelated HCT
- CML Survival, Unrelated PBSC HCT, by Disease Status
- CML Survival, Unrelated Marrow HCT, by Disease Status
- AML Survival, Unrelated HCT, Patients ≥ 55 years
- AML Survival Over Time, Unrelated HCT
- AML Survival, Unrelated PBSC HCT in Adults, by Disease Status
- AML Pediatric Survival, Unrelated Marrow HCT, By Disease Status
- ALL Survival Over Time, Unrelated HCT
- AML Survival, Unrelated Marrow HCT in Adults, by Disease Status
- AML Pediatric Survival Over Time, Unrelated HCT
- ALL Survival, Unrelated PBSC HCT, by Disease Status
- ALL Pediatric Survival Over Time, Unrelated HCT in CR1
- ALL Pediatric Survival, Unrelated Marrow HCT
- ALL Survival, Unrelated Marrow HCT, by Disease Status
- CML Survival Over Time, Unrelated HCT
- MDS Survival Over Time, Unrelated HCT
- Severe Aplastic Anemia Survival in Adults Over Time, Unrelated HCT
- Severe Aplastic Anemia Survival in Pediatric Patients Over Time, Unrelated HCT
- Number of Unrelated Cord Blood Transplants Over Time
- CIBMTR Summary Slides
- Number of Unrelated Donor Transplants, by Patient Age
- AML in Adults, Transplant Consultation Timing Guidelines
- Multiple Myeloma Survival, HCT, by Donor Type
- Mantle Cell Lymphoma Survival, HCT, By Donor Type
- Pediatric AML Transplant Consultation Timing Guidelines
- Diffuse Large B-Cell Lymphoma Survival, Sibling HCT, By Treatment Response
- ALL in Adults, Transplant Consultation Timing Guidelines
- Diffuse Large B-Cell Lymphoma Survival, Autologous HCT, By Treatment Response
- Pediatric ALL Transplant Consultation Timing Guidelines
- Follicular Lymphoma Survival, Sibling HCT, By Disease Status
- Follicular Lymphoma Survival, Autologous HCT, By Disease Status
- Hodgkin Lymphoma Survival, Allogeneic HCT, By Donor Type
- CML Transplant Consultation Timing Guidelines
- Hodgkin Lymphoma Survival, Autologous HCT, by Treatment Response
- CLL Transplant Consultation Timing Guidelines
- NHL Transplant Consultation Timing Guidelines
- Hodgkin Lymphoma Transplant Consultation Timing Guidelines
- CLL Survival, Allogeneic HCT, by Donor Type
- Multiple Myeloma Transplant Consultation Timing Guidelines
- CML Survival, Sibling HCT, by Disease Status
- ALL Survival, Unrelated HCT, Age ≥ 20 yrs, by Disease Status
- ALL Survival, Sibling HCT, Age ≥18 years, by Disease Status
- Other Malignant Diseases Transplant Consultation Timing Guidelines
- ALL Pediatric Survival, Unrelated HCT, by Disease Status
- ALL Pediatric Survival, Sibling HCT, by Disease Status
- MDS Survival, Allogeneic HCT, by Disease Status and Donor Type
- AML Pediatric Survival, Sibling HCT, by Disease Status
- AML Survival, Unrelated HCT, by Disease Status
- Non-Malignant Transplant Consultation Timing Guidelines
- AML Survival, Sibling HCT, by Disease Status
- Indications for HCT
- HCT Activity Over Time, U.S., by Transplant Type
-
Transplant Enews
- BMT caregivers find comfort and support through NMDP/Be The Match services
- BMT Caregivers: Effective support programs tailored to their needs
- BMT Patient Navigators: Extending support and services to assist you and your patients before and after blood or marrow transplant (BMT)
- Shared Decision-Making for Patients with Sickle Cell Disease and their Families
- Psychosocial Interventions: An Essential Component of Comprehensive Care for BMT Patients and Caregivers
- Peer Connect Volunteers Share their Transplant Experiences to Help Others
- Learn About Patient-Centered Outcomes Research
- Individual Counseling Can Help Your Patients and their Caregivers During Difficult Times
- Highlights from BMT Tandem Nursing Meeting: Transplant for Older Adults
- New Online Tool Helps Transplant Patients Learn about Fertility Preservation
- Connect with our Be The Match Patient Support Center Staff
- Applying Evidence to Support Meaning-Making Post-Transplant
- Jason Carter Clinical Trials Program
- Survivorship care plans reduce treatment distress for BMT recipients
- Advances in Transplant Enews
- About Our Research
- Donating Not Once, But Twice to Give a Young Boy Life
- Browse News
-
Browse Research
- A safe and effective shared care approach after allogeneic HCT could be a new standard of care
- Race and ethnicity matching may not impact umbilical cord blood transplant patient outcomes
- Linkage across research databases may provide a more complete understanding of HCT patient outcomes
- Socioeconomic status but not race and ethnicity is likely associated with chronic GVHD outcomes after allogeneic HCT
- Long-term risks of hematological malignancy, autoimmune or thrombotic events do not differ in bone marrow and filgrastim-mobilized PBSC donors
- Novel three-drug combination improves GVHD-free and relapse-free survival and relapse after allogeneic transplant
- Hematopoietic cell donor type may not impact quality of life post-transplant
- Mismatched donor sources may fill an unmet need for patients without fully matched family or unrelated donors
- Structural racism variable accounts for almost all racial and ethnic disparity AML survival
- Lack of collaborative relationships between physician teams associated with HCT care decisions
- Younger matched unrelated donors provide outcome benefits over older matched siblings for MDS patients undergoing allogeneic transplant
- HLA matching in the setting of PTCy improves outcomes in related and unrelated donor HCT
- Less HLA mismatching may provide better outcomes over haploidentical donor HCT in the setting of PTCy
- Age alone should not be a barrier to HCT for adults with AML
- Exploring a standardized approach to measurable residual disease (MRD) testing prior to allogeneic HCT
- Risk predictor tool guides haploidentical donor selection for HCT
- Cryopreservation relieves access issues for patients needing HCT during the COVID-19 pandemic
- Abatacept can reduce racial disparities by mitigating the impact of mismatching in unrelated donor HCT
- 3-Year outcomes remain very good in mismatched unrelated donor HCT patients, highlighting potential to expand access
- Including HLA mismatched unrelated donors and alternative graft sources, Be The Match Registry modeling shows a donor is available for virtually all those in need of HCT
- Assessment of the racial and ethnic diversity on Blood and Marrow Transplant Clinical Trials Network (BMT CTN) trials shows a need to do better
- Creation and evaluation of a Search Summary Score tool for rapid unrelated HCT donor search assessment shows value, particularly for those without a fully matched donor
- NMDP/Be The Match report shows that neither COVID-19 nor cryopreservation prevented allogeneic product infusion
- Early data show COVID-19 vaccination is less effective in those who have undergone cellular transplants in the past year, with more data needed
- HCT provides a significant survival benefit for patients with MDS aged 50 to 75, with no negative impacts on quality of life
- Precision medicine initiative uses whole genome sequencing to identify novel prognostic signatures and the impact of genomic subgroups in MDS allogeneic HCT patients
- Cryopreservation of allogeneic HCT grafts does not adversely impact early post-HCT outcomes
- Abatacept is a promising tool to expand access to HCT, significantly improves survival in 7-8 MMUD HCT
- MUD outcomes are superior to haploidentical HCT for lymphoma in an apples-to-apples comparison
- Access to and outcomes of HCT for adult underserved populations have improved over time, but African American and other pediatric patients still experience a significant disparity
- Addressing barriers to treatment through research and partnership
- BMT CTN 1102 study results support early HCT referral for older patients with MDS
- Rapid donor identification improves survival in high-risk first-remission patients with Acute Myeloid Leukemia
- Further investigation needed on the effect of cryopreserved allogeneic HCT outcomes
- Age not a barrier for successful HCT for AML
- MMUD HCT using PTCY and Bone Marrow is safe and effective, expanding access for diverse populations
- Improving OS and DFS through selective HLA-mismatching in haploidentical related donor HCT
- Novel cytogenetic-based risk scores predict HCT outcomes for patients with CLL
- Are outcomes comparable by age in MAC vs. RIC transplantation for patients with AML in CR2?
- Updated evidence-based guidelines for optimal selection of unrelated donors and cord blood units for HCT
- Allogeneic HCT safe for patients with HIV
- Pre-transplant blinatumomab reduces MRD, time to HCT for pediatric patients with B-ALL
- Comparable long-term outcomes in matched unrelated and sibling donor HCT in older patients with AML
- Shorter response duration and survival after each treatment relapse in MCL
- Haploidentical HCT is viable alternative to matched sibling HCT in patients with AML in CR1
- Gait speed can predict survival, hospital use in older patients with blood cancers
- Using molecular data and MRD status improves HCT survival estimates for adults with AML
- Does age at time of HCT for patients with sickle cell disease impact outcomes?
- Better long-term outcomes with allo-HCT compared to chemotherapy in older patients with AML in CR1
- Geriatric impairments in cancer patients affect caregiver health, QOL
- New clinical practice guidelines for treating multiple myeloma
- Sequential high-dose chemotherapy improves outcomes in adult AML
- Evaluation of new GVHD prevention regimens shows promising results
- New scoring system offers HCT risk stratification for patients with myelofibrosis
- Low-grade aGVHD positively affects OS for patients with early disease stage ALL
- Review: Scientific advances in myelodysplastic syndromes
- Steroid-free treatment rivals prednisone as initial GVHD therapy
- MRD-negative status prognostic for PFS and OS for patients with multiple myeloma
- Neurocognition stabilizes after HCT for patients for sickle cell disease-induced cognitive decline
- Geriatric assessment and targeted interventions recommended for older patients undergoing allogeneic HCT
- Event-free survival improved with midostaurin for patients with FLT3-ITD-mutated AML
- Continued vigilance needed to prevent infections for HCT recipients
- How I treat Philadelphia chromosome positive ALL
- Timing of molecular testing may enhance treatment decisions for patients with AML
- Allogeneic HCT improves 5-year survival for patients over 60 with AML in CR1
- Adding genomic data to new prognostic model improves predictors of post-HCT outcomes in patients with MDS
- Survival has significantly improved in recent years for patients with AML undergoing HCT
- Geriatric assessment helps inform decision making and management for older adults with AML
- Donor-derived LMP-Ts are a safe adjuvant therapy after allo HCT for EBV-associated lymphomas
- Emerging prognostic factors identify older adults with high-risk AML likely to benefit from HCT
- Are the presence of post-HCT mutations in patients with MDS associated with higher risk of disease progression?
- How I Treat Older Adults with Sickle Cell Disease
- Residual disease assessment using next gen-sequencing is predictive of outcomes for patients with AML
- Allogeneic HCT should be considered as first-line treatment for SAA
- Using quality of life to inform treatment decisions for older patients with cancer
- Prognostic factors identified for MDS patients most likely to benefit from induction chemotherapy after HMA failure
- Experts Highlight Latest Advances in Immunotherapies for Hematologic Diseases
- Ruxolitinib Can Prevent Acute GVHD in Patients with Myelofibrosis
- Risk-Adapted Treatment Strategies for Older Patients with AML
- Minimal Residual Disease Identifies Patients Who May Benefit from HCT in First Complete Remission
- Consensus Statement on HCT Late Effects Screening Guidelines in Hemoglobinopathies
- Allogeneic HCT is Feasible for Patients Aged ≥70 Years
- New Prognostic System for Patients with Relapsed Follicular Lymphoma
- Experts Debate Allo-HCT for Patients with Hodgkin Lymphoma Relapsing After Auto-HCT
- Study Compares 5-Year Outcomes of Auto- vs. Allo-HCT in Patients with High-Risk FL
- Delayed Auto-HCT Can Lead to Inferior Survival Rates in Patients with MM
- Spotlight on Novel Therapies to Improve Post-HCT Graft-Versus-Leukemia Effects
- Sorafenib Improves HCT Outcomes in Patients with FLT3-ITD AML
- Second HCT Effective for Subset of Relapsing Children with Acute Leukemia
- HCT Can Be an Effective Treatment for Young Adults with Immune Deficiencies
- Lifestyle Modifications Reduce Risk of Heart Disease after HCT
- HCT and Neurocognitive Dysfunction: Recognizing Risk Factors and Developing Treatments
- Frailty Assessments Can Inform Treatment Decisions in Patients with Hematologic Malignancies
- Study Shows Age Doesn't Affect Survival in HCT for NHL
- Study Shows Age Doesn't Affect Survival Outcomes in Patients with Non-Hodgkin Lymphoma Who Undergo Allogeneic HCT
- Ethical Challenges in HCT for Sickle Cell Disease
- Long-Term Outcomes Show Effectiveness of Reduced-Intensity HCT in MCL
- Auto-HCT Improves Survival in Patients with FL and Early Therapy Failure
- Risk-Stratification Tools for Treating Patients with AML in CR1
- New Scoring Systems for Myelofibrosis Identify Risk Categories Predicting Survival
- Personalized HCT Prognostic Risk Scores Identified for Children with Acute Leukemias
- Study Identifies Key Factors Influencing the Decision to Pursue HCT for Sickle Cell Disease
- Allo-HCT Can Be an Effective Salvage Therapy for Multiple Myeloma
- Ibrutinib Leads to Durable Responses in Steroid-Resistant Chronic GVHD
- Molecular MRD Detection by NGS Predicts Relapse and Survival in Adults with AML
- Lower Relapse and Improved Survival with Mild Acute GVHD after HCT for ALL
- Cyclophosphamide is Effective GVHD Prophylaxis in Matched Related and Unrelated HCT
- HCT Significantly Improves Quality of Life in Children with Sickle Cell Disease
- Early Detection of WT1 Minimal Residual Disease Predicts Outcomes in AML
- Survivorship Care Plans for HCT Recipients Reduce Cancer Treatment Distress
- Prognostic Factors Identified for Optimal HCT Outcomes in Adults with FA
- Review: Racial and Ethnic Disparities in Patients with Hematologic Malignancies
- New Composite Model Predicts Mortality Risk in AML
- Measuring Frailty Can Improve Existing Prognostic Tools
- New Clinical Recommendations on the Role of HCT in Mature T Cell and NK/T Cell Lymphomas
- Report: Strategies for Overcoming Neurocognitive Dysfunction in HCT Recipients
- Auto-HCT Can Be Safe for Myeloma Patients with Renal Insufficiency
- Review: Emerging Therapeutics to Treat Chronic GVHD
- The Current Therapeutic Landscape of FLT3 Inhibitors
- Maintenance with Rituximab Prolongs Survival after Auto-HCT for Mantle Cell Lymphoma
- Haploidentical HCT is Safe and Effective for Older Patients with AML/MDS
- Intermediate-Risk ‘Triple-Negative’ AML at CR1: Improved Outcomes with HCT
- Palliative Care Leads to Improvements in Post-HCT Depression and PTSD
- Case Studies Outline Strategies for Long-Term Monitoring of Adult HCT Survivors
- Expert Panel Issues Practical “How To” Guide on Optimal Cord Blood Transplantation
- Study Identifies Optimal Therapies for Relapsed Pediatric AML
- Disease Risk Index is Important Prognostic Factor for Older HCT Patients
- Vorinostat Can Lead to Lower Incidence of Acute GVHD
- New Patient Care Coordination Model Addresses Complexities of HCT Therapy
- 90% Survival, Low GVHD at Two Years after Alternative Donor HCT for SCD
- Cyclophosphamide Can Lower GVHD Rates in Patients with MM
- Older Patients with MDS: Uncovering Barriers to Allogeneic HCT
- Improved Outcomes and Increased Use of HCT in Patients ≥70 Years
- Immunoglobulin Significantly Reduces Chronic GVHD Rates
- Patients with MDS Responding to HMAs Have Better HCT Outcomes
- Comorbidity Scores are Prognostic of Overall Survival in Relapsed/Refractory AML
- Recent HCT Survival Improvements Reported for Hodgkin Lymphoma
- 30% of Very Young HCT Recipients Experience One or More Late Effects
- Study Finds Disparity in HCT Utilization for Hispanics with Multiple Myeloma
- Which Prognostic Factors Guide HCT Eligibility for Patients with Myelofibrosis?
- Updated Recommendations for Selecting HCT Candidates in Patients with MDS
- New Pre-HCT Counseling Recommendations to Preserve Fertility
- Molecular Genetics Can Predict HCT Outcomes in Myelofibrosis
- Cytogenetic Risk Prognostic of HCT Outcomes in Older Patients with AML in CR2
- Autologous HCT Plus RVD Therapy May Be Best for Patients with MM
- Early Auto-HCT Improves Survival in High-Risk FL Patients
- Allogeneic HCT is Feasible for Patients ≥70 Years
- MRD is a ‘Powerful Predictor for Survival’ in Childhood ALL
- Successful Post-HCT Immune Suppression Discontinuation Factors Identified
- Five-Year Disease-Free Survival Greater Than 80% with Auto-HCT for Hodgkin and DLBC Lymphoma
- Improved HCT Outcomes for Fit Patients with MDS/AML After Standard Conditioning
- Updated Guidelines Identify Factors in Selecting HCT Candidates in Patients with MDS
- Depression Prior to HCT is Prognostic of Lower Survival, Higher Acute GVHD
- Updated ELN Recommendations on the Diagnosis and Management of AML in Adults
- Genetic Alterations Predict HCT Outcomes in Patients with MDS
- Case Study Review: How I Treat Severe Aplastic Anemia
- Multi-Center Study Identifies Biomarkers Associated with HCT Outcomes
- Review: New Targeted Therapies to Treat or Prevent Chronic GVHD
- Report: Long-Term Follow Up Needed after HCT for CLL
- Results Show Non-Myeloablative Haploidentical Transplants Can Be Effective in Pediatric and Young Adult Patients
- Large-Scale Study Shows Greater Than 90% Survival After HCT for Sickle Cell Disease
- Emerging Trends in Managing FLT3-Mutated AML
- No Benefit of Additional Treatment After Auto-HCT for Myeloma with Lenalidomide Maintenance
- Comparable HCT Survival and Incidence of Toxicity for Patients ≥60 Years
- High-Risk Patients with AML Undergoing Early HCT Have Improved Outcomes
- Adults with ALL Experience No Benefit of Consolidation Chemotherapy Prior to HCT
- Adding Sirolimus to Standard GVHD Prophylaxis Significantly Reduces Acute GVHD
- Somatic Mutations Can Improve Transplant Prognostics in MDS
- Reclassified “Low Risk” Patients with MDS Achieve 58% 3-Year OS after HCT
- Tyrosine Kinase Inhibitor Improves Post-HCT Outcomes in Patients with AML
- New NIH Report: Recommended Follow-Up for Long-Term Survivors after HCT
- Alternative Donor HCT Better than Immunosuppressive Therapy in Pediatric SAA
- Careful Selection of Older Patients with MDS Can Improve HCT Outcomes
- Post-HCT Therapies May Improve Outcomes for Patients with High-Risk Myeloma
- ASBMT Report: The Role of Allogeneic Transplant for CLL
- Somatic Mutations Improve Transplant Prognostics in MDS
- MRD Accurately Predicts Survival in Patients with CLL
- MRD-Negativity in Relapsed/Refractory B-Cell ALL Leads to Better HCT Outcomes
- One-Year OS of 86% Achieved with Unrelated Donor HCT for Children with SCD
- Evidence-Based Screening and Prevention Recommendations for Post-Transplant MetS
- Is Cord Blood the Best Alternative Graft Source for Patients with Minimal Residual Disease?
- Review: HCT for Patients with AML in First Complete Remission
- Review: How I Treat the Older Patient with AML
- Pre-Transplant Emotional Support Contributes to Longer Survival
- TKIs Can Effectively Treat Post-Transplant Relapse Risk in Patients with Ph+ ALL
- Pre-HCT Genetic Profiling Can Identify AML Patients at Increased Risk for Relapse
- Better 5-Year QOL after Marrow Transplant than after PBSC Transplant
- Use of TKIs to Prevent Relapse after HCT for Patients with Ph+ ALL
- Biomarker Panel Can Predict Risk of Chronic GVHD
- Higher Post-Relapse Survival with Related or Unrelated HCT than Haploidentical HCT
- BMT CTN: Lessons Learned and Opportunities for the Future
- In Era of Novel Agents, Autologous Transplant Still Preferred Treatment for Multiple Myeloma
- Study Confirms Effective Treatment of Veno-Occulusive Disease Using Defibrotide
- Improved Survival Over Time in Pediatric HCT
- HCT Outcomes in Older Patients with SAA Comparable to Younger Patients
- Comparable Survival, More GVHD Risk Using EBV-Seropositive HCT Donors
- FLT3 Mutation Has No Effect on Survival in HCT for AML
- Early HCT Warranted in Therapy-Related MDS, AML
- Review: How I Treat AML Patients with Preexisting Comorbidities
- Haploidentical and Matched Related Donor HCT Result in Comparable Outcomes
- Expanding Use of HCT to Treat Sickle Cell Disease
- Sustained Long-Term Financial Burden of Allo-HCT on Patients/Caregivers
- Review: Advances in Allo-HCT Expand Use in Older Patients with NHL
- A Biomarker-Guided Prophylaxis Strategy Reduces Acute GVHD
- HCT Yields Over 80% 3-Year Survival and Low Relapse in High-Risk FL Patients
- Prognostic Model Predicts HCT Outcomes in Patients with DLBCL
- Review: HCT Vaccination Guidelines
- Decision-Making Recommendations for Older Adults Considering HCT
- Disease Status, Not Cytogenetics, Predict HCT Outcome in Adult ALL
- Reduced Risk of Chronic GVHD with Post-Transplant Cyclophosphamide
- Scoring System Predicts Transplant Outcomes of Patients with MDS
- Peripheral Blood Stem Cell Donors Recover More Quickly Than Bone Marrow Donors
- Higher Rates of Infection after Marrow Compared to PBSC Transplants
- Haploidentical, Unrelated Donor HCT Outcomes Comparable in Lymphoma
- Better HCT Outcomes Over Time in Children and Adolescents
- Higher Dose of Invariant Natural Killer T Cells Improves HCT Outcomes
- Improved Quality of Life, No GVHD after HCT in Adults with Sickle Cell Disease
- Allo- Better than Auto-HCT for Early Relapsed or Refractory Follicular Lymphoma
- The Role of Pre-Transplant Clonal Burden in Myelodysplastic Syndromes
- Salvage Autologous Transplant Better than Non-Transplant Therapy in Relapsed Multiple Myeloma
- Autologous Transplantation for Multiple Myeloma in the Era of New Drugs
- Risk Factors Identified for Post-HCT Depression, Fatigue
- Review: Maintenance with TKIs Post-Transplant in FLT3-ITD Positive AML
- Meta-Analysis: Outcomes of HCT in Hodgkin Lymphoma Have Improved Over Time
- Children’s Oncology Group: Long-Term Follow-Up Guidelines After Pediatric HCT
- Minimal Residual Disease a Powerful Prognosticator in Standard-Risk AML
- Low Incidence of Late Cardiovascular Complications after Pediatric HCT
- Children Under 3 Years Old Undergoing HCT Require Long-Term Monitoring for Late Effects
- Increased Use of and Improved Survival in HCT for Patients ≥70 Years
- Pre-HCT Depression Leads to Lower Survival, Higher Risk of Acute GVHD
- New Analysis Determines HLA Match Rates in Be The Match Registry
- ATG Significantly Lowers Rate of Chronic GVHD
- Review: Allogeneic HCT to Treat High-Risk Multiple Myeloma
- Improved Outcomes in HCT Recipients with Acute GVHD Over Time
- Minimal Residual Disease Best Method to Define Complete Remission in AML
- AML Review Series in Blood Highlights Latest Advances
- Prognostic Model Identifies Relapsed DLBCL Patients Who Can Achieve Durable Progression-Free Survival After Allogeneic HCT
- Azacitidine Feasible as a Bridge to HCT in Patients with Higher-Risk MDS or Low-Blast Count AML
- New Scoring System Predictive of HCT Outcomes in Patients with MDS
- 95% One-Year HCT Survival for Adults with Sickle Cell Disease
- Comparable Outcomes in Unrelated Donor vs. Haploidentical HCT with Cyclophosphamide
- Quality of Life Better After Marrow Transplant Than After PBSC Transplant
- Three-Year Survival of 94% in HCT for Sickle Cell Disease
- HCT for Relapsed or Refractory Follicular Lymphoma Leads to 5-Year Survival of 52%
- Survival 80% or Higher with Allogeneic HCT after Failed Autologous HCT for Lymphoma
- Survival 65% or Higher in HCT for Progressive or Refractory Follicular Lymphoma
- Better HCT Outcomes in Younger Adults with T-Cell ALL
- Meeting the Needs of HCT Recipients Transitioning from Childhood to Adulthood
- Higher Relapse-Free Survival with Myeloablative HCT in Patients with AML and MDS
- Early HCT for SCD in Children is Preferred Therapy Prior to Onset of SCD Complications
- Patients Age 65 Years and Older with MDS Should Not Be Limited from Undergoing HCT
- Pre-Transplant Patient-Reported Physical Health Predicts Post-Transplant Mortality
- Review: HLA-Identical Sibling HCT to Treat Sickle Cell Disease in Children
- Low Non-Relapse Mortality, GVHD after HCT in Older Patients with AML in First Remission
- Meta-Analysis: Age Not a Determining Factor in HCT Selection for AML
- Review: Indications for Allo-HCT in Primary Myelofibrosis
- Consensus Report: Salvage Therapy with HCT for Relapsed Multiple Myeloma
- AML patients ≥70 Achieve 60% Estimated Survival with UCB HCT
- Review: Acute Myeloid Leukemia
- HCT Yields Best Outcomes in Patients ≥60 Years with AML
- A Refined Acute GVHD Risk Score Can Predict HCT Outcomes
- Excellent Outcomes in Outpatient Autologous HCT for Patients with Myeloma or Lymphoma
- Biomarkers Predict Severity of GVHD after HCT
- GVHD Marker Found in HLA-DPB1 Mismatched HCT
- Non-Myeloablative Haploidentical HCT in Older Patients
- Review: Treating T-Cell ALL in Adults
- Ruxolitinib Effective in Treating Steroid-Refractory GVHD
- Allogeneic HCT Better than Autologous HCT for Progression-Free Survival in Follicular Lymphoma
- T Cell-Depletion Yields Low Rates of Chronic GVHD, Relapse in Patients Transplanted for AML
- Parallel Phase 2 Trials Confirm Utility of Both Haploidentical and Cord Blood HCT
- Progress Report: Update of BMT CTN State of the Science Symposium
- Tacrolimus-Sirolimus Comparable to Tacrolimus-Methotrexate as GVHD Prophylaxis
- MMF Plus Corticosteroids Does Not Improve Acute GVHD Treatment Over Corticosteroids Alone
- Novel Agents for Consolidation and Maintenance Therapy After Auto-HCT for Multiple Myeloma
- Review: Treating Early Relapsed and Refractory AML
- ASBMT Guidelines: Indications for Autologous and Allogeneic HCT
- Lenalidomide after Autologous HCT for Multiple Myeloma Improves Survival
- No Clinical Benefit in Adding Radioimmunotherapy to BEAM Conditioning in Autologous HCT for Relapsed DLBCL
- BMT CTN Study to Compare HCT to Hypomethylating Agents to Treat MDS
- Comparable Survival in Clinical Trial Participants vs. Nonparticipants
- Haploidentical vs. Matched Unrelated HCT for AML
- Improved Outcomes in Alternative Donor HCT for Fanconi Anemia
- Review: ALL in Older Adolescents and Young Adults
- Validation of HCT Comorbidity Scoring: Improving Therapy Selection
- Comparable Outcomes in Haploidentical, Unrelated Cord Blood HCT
- Level of HLA Match Affects Outcomes in Reduced-Intensity HCT
- ASBMT Evidence-Based Review: The Role of HCT in Multiple Myeloma
- Review: Treatment Options for Adults with Relapsed or Refractory Ph- ALL
- Extramedullary Disease in AML Does Not Affect HCT Outcomes
- Comparable Survival in Cord Blood, Mismatched Unrelated HCT for AML
- Review: Complementary and Alternative Medicine Use among HCT Recipients
- Multi-Center Validation of the Prognostic Value of the HCT-Specific Comorbidity Index
- Simple Procedure Offers Significant Advances in Umbilical Cord Blood HCT
- ASBMT Evidence-Based Review: The Role of HCT in Hodgkin Lymphoma
- Long-Term Study of HCT in Hurler Syndrome: Impact of Timing and Non-Carrier Donors
- Outcomes of Extracorporeal Photopheresis Better in Early Stage GVHD
- Review: Role of HCT for CML in the 21st Century
- New Guidelines for Secondary Solid Cancer Screening Following HCT
- Comparable HCT Outcomes for Patients with de novo or Secondary AML in CR1
- Haploidentical HCT with Cyclophosphamide for High-Risk Leukemias
- Younger Donor Age Correlates with Higher CD-8 T Cell Counts, Better HCT Outcomes
- Allogeneic HCT for Acute Biphenotypic Leukemias
- Long-Term Outcomes after HCT for Mantle Cell Lymphoma
- Excellent HCT Outcomes in Fanconi Anemia without Radiation
- Excellent Survival in Pediatric Cord Blood Transplant for Non-Malignant Disorders
- PET Scans Predict Relapse in Patients with NHL
- Review: Post-Transplant High-Dose Cyclophosphamide to Prevent GVHD
- No Impact of Patient Age on Survival in Reduced-Intensity HCT
- Review: Reduced-Intensity HCT in Adults with AML
- AZA, DLI Effective Therapy for MDS, AML with Low Disease Burden
- Related, Unrelated HCT Outcomes Comparable in Pediatric ALL
- Validated Chronic GVHD Risk Score Can Predict Major HCT Outcomes
- Review: How I Treat JMML
- Post-HCT Fungal and Viral Infections: Improving Outcomes over Time
- Autologous, Allogeneic HCT Both Effective in Pediatric High-Risk AML
- HCT Better than Chemotherapy As Post-Remission Therapy for AML Patients Age 40-60
- Lower Risk for Serious Adverse Events and No Increased Risk for Cancer after PBSC vs BM Donation
- Report: BMT CTN 2014 State of the Science
- Donor vs. No Donor Study: Better Outcome with Allo-HCT in NPM1-Mutated AML
- Marrow, Peripheral Blood Yield Comparable 5-year Survival in Reduced-Intensity HCT
- Review: Collaborative Partnerships to Manage Patients with Chronic GVHD
- Treosulfan-Based Conditioning and HCT for Nonmalignant Diseases
- Survival of Patients with AML Relapsing after Allogeneic HCT
- Alternative Donor HCT for Lymphoma Patients Lacking an HLA-Matched Donor
- Post-HCT Cyclophosphamide is Effective as Sole GVHD Prophylaxis
- Adding an Ex Vivo Expanded Cord Blood Unit Improves Engraftment
- HIV-1 Infection Shouldn’t Preclude HCT for Lymphoma
- FLT3 Mutation Affects Relapse, But Not Survival after HCT for AML
- Allogeneic HCT Better than Chemotherapy, Autologous HCT in Intermediate-Risk AML
- Pre-Transplant Conditioning with Rituximab Yields Good Outcomes in Adults with Follicular Lymphoma
- Post-Transplant Cyclophosphamide Yields Comparable Outcomes Across Donor Types and Conditioning Regimens
- Pre-Transplant, Patient-Reported Quality of Life is Prognostic for Transplant Outcomes
- Reduced-Intensity HCT Significantly Improves Survival in Elderly Patients with AML in CR1
- Long-Term Impact of TBI on Cognitive Functioning in Pediatric HCT
- Comparable Transplant Outcomes in AML Regardless of Donor Source
- HCT Prognostic Index Guides Clinical Decision-Making
- Similar Survival Rates in Children Transplanted with One vs. Two Umbilical Cord Blood Units
- Specific HLA Alleles Associated with Development of Severe CLL
- High-Risk CLL: Current Treatment Considerations with Novel Agents and HCT
- Review: HCT for Patients with AML in First Remission
- Significant Improvement in Survival of Unrelated-Donor HCT Over Time
- Front-Line Allo- or Auto-HCT Prolongs Survival in Young Patients with PTCL
- Consensus Report: The Role of Autologous and Allogeneic HCT in MCL
- Review: Donor Selection for Adults Lacking a Matched Related or Unrelated Donor
- Review: HCT for Myeloproliferative Neoplasms in the Era of Tyrosine Kinase Inhibitors
- High-Resolution HLA-A, -B, -C, -DRB1 Matching Yields Optimal Survival in Unrelated HCT
- Early Transplant Best in SCID Infants
- Consensus Report: Optimal Benefits Packages for HCT Focused on Outcomes
- Younger, Older HCT Recipients Have Comparable QOL
- Review: Next Generation Treatment of Acute GVHD
- Review Series in Blood Journal: Advances in HCT
- Review: HCT and Novel Approaches in Pediatric ALL
- Review: Critical Need for Long-Term Follow-Up Care after HCT
- Novel Conditioning Regimen Permits HCT for Adults with Severe SCD
- Favorable Overall Survival Results for Allogeneic HCT in Patients with Multiple Myeloma
- Review: Pre-HCT Cytoreductive Treatment in Patients with MDS
- High Likelihood that Patients Needing Unrelated HCT Will Find Donor on Be The Match Registry
- Review: Novel Approaches to Treat Acute GVHD
- Review: Factors Affecting Selection of a Pre-HCT Conditioning Regimen
- Better QoL for HCT Survivors with Umbilical Cord Blood vs. Matched Sibling Donors
- Review: How I Treat Relapsed AML in Children
- No Effect of Pre-HCT Cytoreduction in MDS
- HCT in Sickle Cell Disease and Thalassemia: Evidence-Based Focused Review
- Lenalidomide Maintenance after HCT for High-Risk Multiple Myeloma
- Geriatric Assessments Can Predict HCT Outcomes in Older Adults
- Long-Term Study Shows HCT Survival Increasing over Time
- Pre-Transplant Comorbidities Predict Severity of Acute GVHD
- Large-Scale Study Validates Prognostic Value of HCT Disease Risk Index
- Pre-Transplant ATG Protects against GVHD in MDS
- WMDA Report: Unrelated Donor Medical Suitability
- HCT Outcomes Improving over Time in Teens and Young Adults with ALL
- Review: Preserving Fertility in HCT Recipients
- Encouraging Progression-Free Survival in HCT for Older NHL Patients
- A Contemporary Analysis of the Impact of HLA Mismatch on HCT Outcomes
- Impact of the Affordable Care Act on HCT
- Identifying Impact of Donor/Recipient Sex Match in Cord Blood Transplant
- Extracorporeal Photopheresis Induces Responses in Chronic GVHD
- Pre-Transplant Imatinib Benefits Adults with Ph+ ALL
- Pre-Transplant 5-AZA Provides Disease Control in High-Risk MDS
- IPSS-R and Monosomal Karyotype Predict HCT Outcomes in MDS and AML
- Post-HCT Minimal Residual Disease Can Identify Impending Relapse in Pediatric ALL
- Study Supports Salvage HCT for Relapsed Core Binding Factor AML
- Double Cord Blood HCT Suitable Alternative to Unrelated Donor HCT in High-Risk Patients
- Early Transplant in SCID Infants Free from Infections Results in Excellent Outcomes
- Geriatric Assessment has Independent Prognostic Utility in Older HCT Recipients
- Reduced-Intensity HCT for Chronic Granulomatous Disease
- Pre-Transplant MRD Predicts HCT Outcome in AML
- Longer-Term HCT Outcomes for Severe Sickle Cell Disease in Childhood
- No Effect of Pre-Transplant Cytarabine Consolidation on AML Transplant Outcomes
- Related, Unrelated Donor HCT Comparable in DLBCL
- NCI Report: Prevention and Treatment of Relapse after Allo-HCT
- No Significant Difference in Long-Term Experiences of Marrow, PBSC Donors
- Blood “How I Treat” Series: Higher-Risk MDS
- Early Transplant Best in Chemotherapy-Sensitive MCL
- HCT in CR1 Beneficial to Outcomes for Older AML Patients
- Comparing Chemotherapy to Allo-HCT in Post-Remission AML
- Peri-Transplant Rituximab in Lymphoma Can Lead to Durable Event-Free Survival
- Imatinib to Treat Steroid-Refractory Chronic GVHD
- Review: Strategies to Improve Outcomes of Unrelated Donor PBSC Transplants
- Review: Options for Patients with Refractory Aplastic Anemia
- Comparable Outcomes for Unrelated, Sibling HCT in Aplastic Anemia
- Improved HCT Survival over Time for Adolescents and Young Adults
- Risk Factors in HCT for Cytogenetically Normal AML
- Childhood HCT Survivors Require Life-Long Monitoring for High-Risk Complications
- Inhibition of IL-6 Can Offer “Profound Protection” from Acute GVHD
- Comparable Outcomes for Unrelated Donor, Cord Blood HCT in Lymphoma
- Unrelated Donor, Cord Blood Grafts Yield Extended Survival in Older AML Patients
- Prior Therapy Does Not Affect Transplant Outcomes in High-Risk MDS
- Review: Comparing HCT Donor Options in Ph- ALL
- Report: The Role of HCT in Treating HIV
- Understanding Factors in Long-Term HCT Outcome in Fanconi Anemia
- Reduced-Intensity HCT for Primary Myelofibrosis is Potentially Curative
- Personalized Prognostic Information for Adult Leukemia Survivors after HCT
- IV Busulfan Better Than TBI in Pre-Transplant Conditioning
- IV Busulfan Better Than TBI in HCT for AML in CR1
- Meta-Analysis: HCT Does Not Affect Cognitive Functioning in Adults
- Immune-Modulating Drugs, Hypomethylating Agents to Treat Relapse
- Comparable Survival in Cord Blood and Adult Donor HCT for ALL
- Review: How I Treat SCID
- Report: HCT Trends in Europe
- QOL More than 20 Years After HCT for Thalassemia
- Better HCT Outcomes with Younger Unrelated Donors vs. Older Related Donors
- Unrelated Donor HCT is Underused in the United States
- Post-HCT Rituximab Prophylaxis Can Reduce Chronic GVHD
- Report: Prophylaxis and Treatment of GVHD
- Lower Chronic GVHD in Double Cord Blood HCT
- Study Predicts More Than 500,000 HCT Survivors by 2030 in U.S.
- Earlier HCT Improves Outcomes in T-cell NHL
- Updated Guidelines on HCT Graft Selection
- Marrow, PBSC Have Comparable Survival; More cGVHD with PBSC
- New Autoimmune Diseases after Cord Blood Transplantation
- Review: The Role of Sirolimus in GVHD Management
- Long-Term Follow-Up of HCT Recipients Made Easier
- Review: Cord Blood Transplant Supported by Third-Party Donor Cells
- Myeloablative HCT Improves Survival in Younger Adults with ALL in First Remission
- How I Assess Comorbidities Prior to HCT
- AZA and DLI for Relapsed AML/MDS After HCT
- HCT for Chemorefractory Mantle Cell Lymphoma
- Risk-Stratified Adoptive Cellular Therapy After HCT for CLL
- Graft-Versus-Tumor Effects in Advanced Malignancies
- Allogeneic HCT for Neuroblastoma
- Allogeneic HCT in AML patients in second remission
- The Myth of CR2 in Adult Acute Leukemia
- HCT Outcomes Comparable in High- and Standard-Risk Pediatric AML
- Long-Term Follow-Up of Caregivers for HCT recipients
- Autologous, Allogeneic, or Chemotherapy for Transformed Follicular Lymphoma
- Emerging Therapies for Chronic Cutaneous GVHD
- Review: Minimal Residual Disease in Acute Leukemia
- Comparable Outcomes in AML/MDS Using Related, Unrelated Donors
- Review: HCT for Burkitt lymphoma
- To Transplant or Not: Clinical Decisions in Elderly Patients with AML
- How I Treat Older Patients with ALL
- Cord Blood HCT: The first 25 Years and Beyond
- Review: Allogeneic HCT for Diffuse Large B Cell Lymphoma
- Significant Improvement in HCT Survival Over Time
- Outcomes for HCT in Patients Over Age 70
- Similar Survival Using Sibling, Unrelated Donor, and Cord Blood Grafts in AML
- Negative Impact of Minimal Residual Disease is Similar for AML in CR1 and CR2
- Comparing Transplant vs. Non-Transplant for De Novo MDS by IPSS Score
- Related, Well-Matched Unrelated HCT Outcomes Comparable in MDS
-
- National Marrow Donor Program®/Be The Match® and CIBMTR® (Center for International Blood and Marrow Transplant Research®) note studies of older adults with MDS demonstrate significant survival benefit
- Why race matter in transplants cellular therapies
- Understanding and meeting the psychosocial needs of sibling donors
- Beth Murphy Retires
- Connect with our Be The Match Patient Support Center Staff
- Free support groups provide patients and caregivers opportunities to connect
- Mindfulness interventions help to reduce distress symptoms for hospitalized patients with blood cancers
- New tool improves prediction of post-BMT outcomes in patients with MDS
- Free program streamlines clinical trial searches
- Bone Marrow Transplants: More Than Just Survival
- National Marrow Donor Program® Be The Match® Applauds Congress for $5 Million Boost to Vital Programs
- Study Shows Age Doesn’t Affect Survival Outcomes in Patients with Non-Hodgkin Lymphoma Who Undergo Allogeneic HCT
- National Marrow Donor Program® Be The Match® Applauds New Legislation to Protect Patient Access to Life-Saving Transplants for Medicare Beneficiaries
- Be The Match BioTherapies Announces Collaboration Agreement with Magenta Therapeutics
- Nation’s Bone Marrow Program Formally Requests Additional Funds from Congress to Address Growing Patient Need for Life-Saving Transplants
- National Marrow Donor Program (NMDP) Be The Match Forms New Cellular Therapies Subsidiary
- The National Marrow Donor Program Be The Match Applauds Reps. Jolly and Matsui for Creating Congressional Caucus to Increase Awareness about Transplants
- Fire Department of New York Presented with Rod Carew Leadership Award
- International Marrow Donor Registries Reach 25 Million Potential Donors
- HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment
- Roadmap to Future BMT CTN trials focus of Pre-ASH symposium
- Similar Survival Rates in Children with High Risk Blood Cancers Transplanted with One Versus Two Umbilical Cord Blood Units
- Large Majority of Patients Who Need Unrelated Bone Marrow Transplants Can Find a Matching Donor on the National Be The Match Registry
- Case-Based CME Shares Latest CLL and MCL Research and Outcomes
- Be The Match Partners with Illume to Pay Tribute to Mothers and Caregivers
- Ever Wonder What Happens to a Cheek Swab After Someone Joins Be The Match Registry?
- Falcons Linebacker Laces Up for Be The Match
- Dr. Mary Horowitz Presented with Lifetime Achievement Award for Blood and Marrow Transplant Research
- Be The Match Walk+Run 2014 Dates and Cities Announced
- Robin Roberts Collaborates with Be The Match and Stand Up To Cancer
- “With true gratitude and love in my heart, I knew that I needed to give back in some way.”
- Love Conquers All - Bone Marrow Transplant Nurse Shares Her Own Transplant Journey
- 22-Year-Old Aruni Donated PBSC in Honor of a Member of Her Community
- Race Matters When a Patient Needs a Stem Cell or Marrow Transplant
- Life: The Most Precious Gift
- A Home for the Holidays
- New Day Celebrates Giving the Tuesday after Thanksgiving
- Sealed With A Promise (S.W.A.P.) Bracelet Now Available
- Latest Developments in CLL and MCL
- Abby’s “Destiny to Donate Marrow”
- Giving a Child the Gift of Life
- In Memoriam: Congressman C.W. Bill Young
- Transplant Patient and Doctor Take Coastal Bike Ride Together
- American Express Is First To Provide Grant to Support Online Registration for Be The Match
- Run-Walk Fundraising Event Expands
- Coalition Says PBSC Donor Compensation Poses Health Risks to Patients and Donors
- Marrow Transplant Patient Shares Jazz Compositions
- ASBMT Joins the NMDP to Support the Amy Strelzer Manasevit Research Program
- A Father Pays it Forward
- Wife of Supercross champion, Jeremy McGrath, waits for her transplant
- Good Morning America Anchor, Robin Roberts announces MDS diagnosis
- Cancer Survivor Hits the Road with Milwaukee Brewers
- Dwight and Ray—More in common than most brothers
- Marrow Transplant Patients and Advocates Rally Congress to Support Be The Match
- 'This can't be happening to me...' Mother of Three Thrives After Marrow Transplant
- Mother of two will finally meet the young man who saved her life
- Donor and Recipient Meet for First Time on ABC’s Good Morning America
- ABC’s Robin Roberts Teams up with Be The Match to Help Save Lives
- “You Made a Choice that Many People Don’t Make.” Parent’s Personal Thank You to Donor
- Robin Roberts Asks America, “If You Had the Power to Save a Life, Would You?”
- Be The Match Focuses on Building a Younger Registry
- Study Compares Unrelated Marrow and PBSC Transplant Outcomes
- Recipient and Donor Overcome Together
- Eleven Awards Honor Outstanding Contributions to Be The Match
- “Thanks to you, my recipient and I can be ‘bone buddies’ forever”
- New Research Shows Significant Improvement in Survival
- 1 Millionth Blood Stem Cell Transplant Marks Major Medical Milestone
- “They Were All So Proud, But to Me, It Was a ‘No Brainer.’”
- Be The Match Marshals Social Volunteers to Help Save Lives on MLK Day of Service
- Know Your Risk Factors for Developing Heart Problems After Transplant
- World-Champion Boxer Robert Guerrero Teams Up With Be The Match
- “I Walk for People Who Have Nothing Left Except Hope.”
- Robin Roberts Returns to Good Morning America After Transplant
- Three-Year-Old Ben Fought for His Life and Won
- 'Team Tanner' Family, Friends and Hockey Community Celebrate Tanner’s Life
- Thrilled by the Miracle that I Was Chosen as a Match!
- Skin GVHD: How to Spot and Tips to Manage
- New Research Shows Significant Improvement in Overall Survival Outcomes for Patients Receiving Blood Stem Cell Transplants
- Craving Connections After Transplant: Young Adults Reach Out to Peers for Hope and Healing
- “A Cord Blood Donation Saved My Life After Relapse” - Krista's Story
- What Hurricane? Firefighter, Craig Donates during Rita
- Two-Time Donor Describes Donation as “The Best Feeling”
- National Marrow Donor Program (NMDP) Names Amy Ronneberg CFO
- NMDP/Be The Match Named Top Minnesota Workplace
- Cord Blood Transplant Renews Teen's Health and Perspective on Life
-
Education Catalog
-
About Us
- Transplant Indications and Outcomes
- Resources
-
- LifeSouth's Cord Blood Bank: Umbilical Cord Blood Collection Training for Public Donation
- StemCyte CBB OB Training: Umbilical Cord Blood Collection Training for Public Donation
- GenCure CBB OB Training GenCure - Texas Cord Blood Bank: Umbilical Cord Blood Collection Training for Public Donation
- Download HCT Guidelines Thank You